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Abstract
In a double-blind, controlled study, we examined the
therapeutic effects of high-frequency left prefrontal
repetitive transcranial magnetic stimulation (rTMS)
on schizophrenia symptoms. A total of 22 chronic hos-
pitalized schizophrenia patients were randomly
assigned to 2 weeks (10 sessions) of real or sham
rTMS. rTMS was given with the following parame-
ters: 20 trains of 5-second 10-ELz stimulation at 100
percent motor threshold, 30 seconds apart Effects on
positive and negative symptoms, self-reported symp-
toms, rough neuropsychological functioning, and hor-
mones were assessed. Although there was a significant
improvement in both groups in most of the symptom
measures, no real differences were found between the
groups. A decrease of more than 20 percent in the total
PANSS score was found in 7 control subjects but only
1 subject from the real rTMS group. There was no
change in hormone levels or neuropsychological func-
tioning, measured by the MMSE, in either group. Left
prefrontal rTMS (with the used parameters) seems to
produce a significant nonspecific effect of the treat-
ment procedure but no therapeutic effect in the most
chronic and severely ill schizophrenia patients.
Keywords: rTMS, schizophrenia, prefrontal
hypometabolism, RCT.
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Repetitive transcranial magnetic stimulation (rTMS) of
the left dorsolateral prefrontal cortex (DLPFC) has been
studied mainly as a therapeutic tool for major depression
(Pascual-Leone et al. 1996; George et al. 1997). High-fre-
quency rTMS has been reported to normalize the hypoac-
tive left DLPFC found in some depressed patients
(George et al. 1995).
There have been reports that patients with schizo-
phrenia have decreased metabolic activity in the pre-
frontal cortex (Andreasen et al. 1997). In a volumetric
study on schizophrenia patients, negative symptoms cor-
related with white matter reductions in the prefrontal
region (Sanfilipo et al. 2000). Functional imaging studies
have suggested that hypoactivity of the left DLPFC corre-
lates with psychomotor poverty or retardation (Wolkin et
al. 1992). Moreover, a preliminary study suggests that
DLPFC function actually mediates negative symptoms
(Nahas et al. 2000).
Some preliminary rTMS studies have demonstrated
improvement in mood (Geller et al. 1997) and in anxiety
and restlessness (Feinsod et al. 1998) as well as in nega-
tive symptoms (Cohen et al. 1999) in schizophrenia
patients. A single case of beneficial effects of rTMS in
catatonia has been published (Grisaru et al. 1998).
Three treatment studies of rTMS in schizophrenia
patients have been published thus far; low-frequency left
temporoparietal rTMS seems to reduce auditory halluci-
nations in schizophrenia patients (Hoffman et al. 2000),
low-frequency right prefrontal rTMS over 2 weeks had no
effect on symptoms of schizophrenia (Klein et al. 1999),
and high-frequency left prefrontal rTMS showed some
therapeutic effect on symptoms in a recent preliminary
study (Rollnik et al. 2000). We examined the effect of left
DLPFC rTMS for 2 weeks in schizophrenia patients in a
parallel group, randomized double-blind controlled trial.
Method
We recruited 22 chronic inpatients from Vanha Vaasa
Hospital, a state mental hospital in western Finland, with
a Structured Clinical Interview for D5Af-/V-verified
(SCID; First et al. 1995) DSM-IV diagnosis of schizo-
phrenia (APA 1994). Of these patients, 19 were men and
20 were right-handed. Those with major physical or neu-
rological abnormalities were excluded. After a complete
description of die study was presented, written informed
consent was obtained and patients were randomly
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assigned to real or sham treatment. Concealment of the
allocation was guaranteed by opening the closed random-
ization envelopes just before the first stimulation of the
first session. Of the 22 patients, 10 had paranoid, 1 cata-
tonic, 3 hebephrenic, 6 undifferentiated, and 2 residual
schizophrenia.
At baseline, the groups receiving active rTMS and
sham stimulation did not differ significantly in gender,
inpatient status, or history of alcohol abuse. Their mean
ages were 38.5 (standard deviation [SD] = 10.2) and 34.8
(SD = 9.8), respectively. The mean duration of the current
hospitalization was 4.2 (SD = 4.6) and 4.5 (SD = 4.0)
years, and the total duration of the illness was 13.5 (SD =
8.9) and 12.9 (SD = 12.0) years, respectively. The mean
Positive and Negative Syndrome Scale (PANSS; Kay et
al. 1987) total value, indicating the severity of the illness,
was 105.2 (SD = 41.2) and 110.3 (SD = 20.2), respec-
tively. There were no statistically significant differences in
any of the baseline values.
We allowed an unlimited but stable concomitant drug
therapy. Among the 11 patients receiving rTMS, concomi-
tant drug therapy mainly consisted of clozapine for 7
patients (1 combined with risperidone, and 1 with olanza-
pine), olanzapine for 2, quetiapine for 1, and
zuclopenthixol for 1 patient. The mean chlorpromazine
equivalent dose was 1,168 mg. In the rTMS group, 4 also
received a selective serotonin reuptake inhibitor (SSRI), 3
were on a mood stabilizer (valproate or oxcarbazepine at
a therapeutic level), and 5 received benzodiazepines
(mean lorazepam equivalent dose 4.6 mg).
Among the 11 patients receiving sham treatment,
concomitant drug therapy consisted mainly of clozapine
for 7 patients and olanzapine for 4 patients. The mean
chlorpromazine equivalent dose was 1,309 mg. In the
sham group, 4 also received an SSRI, 3 were on a mood
stabilizer (valproate or oxcarbazine at a therapeutic level),
and 3 received benzodiazepines (mean lorazepam equiva-
lent dose 4 mg). There were no statistically significant dif-
ferences in concomitant antipsychotic or other drug treat-
ments between the two groups. The doses of the drugs
were stable throughout the trial.
Transcranial magnetic stimulation was administered
by a 70-mm figure eight-shaped coil (Magstim Co., U.K.)
to the left DLPFC (measured as 5 cm anterior to the opti-
mal site for activating the right abductor pollicis brevis)
with the following safety guideline-fulfilling characteris-
tics: 10 Hz, 100 percent motor threshold, 20 trains of 5
seconds each, 30 seconds apart. The stimulation parame-
ters were taken from earlier depression studies and have
been suggested to have DLPFC-activating properties
(e.g., Pasqual-Leone et al. 1996). The threshold was deter-
mined at rest with surface electromyography, by using the
method of limits (i.e., the intensity required to evoke at
least a 50-u.V peak-to-peak potential in four out of eight
trials over the optimal site). The coil was tangential to the
scalp at 45° to the parasagittal line, with the handle point-
ing backward in the real rTMS condition. In the sham
condition, the coil was held at 90° to the scalp with both
wings touching the scalp.
Psychiatrists (M.E., K.T., P.T.) blind to the treatment
groups assessed symptoms at baseline and at the end of 2
weeks' rTMS. The Mini Mental State Examination
(MMSE; Folstein et al. 1975), for rough cognitive func-
tioning, and the PANSS were assessed at both time points.
Serum cortisol, thyroid-stimulating hormone (TSH), and
prolactin concentrations as well as the motor threshold
were measured at these time points. A self-report ques-
tionnaire, Symptom Checklist-90 (SCI^90; Derogatis et
al. 1973), was filled out by the patients at pre- and
posttesting. Self-reports are rarely used with psychotic
patients, but we used the SCL-90 along with the PANSS
to get patients' subjective views on the possible symptom
change.
The rating scale scores and the laboratory values for
all patients were analyzed for change over the 2-week
treatment period. A paired sample 2-tailed t test was used
to examine the significance of change within the groups.
The size of any change in the rTMS and sham groups was
compared by an independent sample 2-tailed t test.
Intention-to-treat analysis was used, and a 20 percent
decrease in the patient's total PANSS score was defined as
our primary outcome measure.
Results
Seven patients of the sham group but only one of the
rTMS group were improved according to our primary out-
come measure—a 20 percent decrease in the total PANSS
score. The chi-square test indicated a statistically signifi-
cant difference between the groups (Fisher's 2-sided exact
test, p = 0.024).
There were no significant differences between the
two groups in the different PANSS scales. A significant
improvement over the 2 weeks in all the PANSS scales
was found within the sham group, whereas within the
rTMS group significant improvement was found in only
the positive symptom scale and the total PANSS score
(table 1).
There were no significant differences between the
two groups in the self-report measures (table 1).
No significant changes were found in the hormone
levels, aside from a small decrease in the TSH value
within the sham group. No differences between the groups
were found in the hormone levels.
There was a slight increase in the motor threshold in
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between the two groups was found. There was no change
in the MMSE scores within either group.
In the rTMS group no significant differences were
found in any of the outcome measures between those who
were on anticonvulsant drugs and those who were not. No
differences were found in the outcome measures between
those using benzodiazepines and those not using them,
apart from the PANSS general symptoms scale, where
those using benzodiazepines improved significantly more
(2-tailed independent samples t test, p = 0.036) than did
the nonusers.
One patient in each group dropped out because of
paranoid thoughts about the treatment. The sham group
dropout had received 5 days of treatment and could be
rated at the end of the 2-week period, whereas the rTMS
dropout stopped the trial during the first session and
refused further ratings. No seizures or other side effects,
besides a mild headache in three patients of the rTMS
group, occurred during the trial. Most of the patients in
the rTMS group (8 out of 11) but none in the sham group
considered the stimulation painful.
Discussion
The results suggest that high-frequency rTMS of the left
DLPFC with the parameters used in this study does not
have significant therapeutic effects in severe schizophre-
nia- Our results do not support the preliminary finding that
high-frequency rTMS to the left DLPFC improves symp-
toms of schizophrenia (Nahas et al. 2000; Rollnik et al.
2000).
This study detected an impressive nonspecific effect
for the entire rTMS procedure but no specific effect for
the magnetic brain stimulation. In earlier rTMS studies,
the possibility of active sham forms has been discussed
(Loo et al. 2000). In this study, the coil was held at 90° off
the scalp, which does not give a rTMS-like scalp sensa-
tion, but also causes no stimulation to the cortex, thus rul-
ing out the possibility of an active sham (Loo et al. 2000).
Rollnik's high-frequency rTMS study used a crossover
design, and the stimulation coil was at 45° off the scalp
under the sham condition (Rollnik et al. 2000), thus mak-
ing a carryover effect possible.
Our study sample was small, which creates the possi-
bility of a type II error. However, the control group
seemed to improve more than the rTMS group, although
not statistically, which reduces the possibility that we did
not detect an existing rTMS effect. Interestingly, self-
reported symptom severity was the only measure where
only the rTMS group improved significantly (0.5 SD
improvement). Still, as in the other measures, there was
no statistical difference between the groups. The finding
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the groups is similar to a recently published finding
(Dolberg et al. 2002).
The patients in our study were chronic, severely ill
(PANSS > 100), heavily medicated schizophrenia
patients, which may partly explain the lack of effect for
this short treatment period. The patients in Rollnik et al.'s
study (2000) were less severely ill and were not reported
to be using anticonvulsant drugs. In Hoffman et al.'s study
(2000), anticonvulsant drugs reduced the rTMS effects,
which is not probable in this study, because there was no
difference in the outcome of users and nonusers of these
drugs. Also, the use of benzodiazepines could theoreti-
cally reduce the rTMS effect, as they have been reported
to reduce cortical excitability (Ziemann et al. 1996). In
this study, the only difference between users and nonusers
of benzodiazepines was found in the PANSS general
symptoms scale, and surprisingly, it favored the users.
Rollnik et al. used fast rTMS of slightly different
characteristics (e.g., they employed 20 Hz frequency,
while this study used 10 Hz frequency), which may partly
explain the different result
Finally, the malfunctioning at the prefrontal cortex in
patients with chronic schizophrenia may involve mecha-
nisms different from those involved in depression. The
malfunctioning may be, even if qualitatively similar, more
permanent than in depressive patients, consequently
requiring longer treatment periods (e.g., Dolberg et al.
2002) or stronger stimulation (possibly even outside pub-
lished safety guidelines) to produce a response.
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